Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
D J McGrail
,
P G Pilié
,
N U Rashid
,
L Voorwerk
,
M Slagter
,
M Kok
,
E Jonasch
,
M Khasraw
,
A B Heimberger
,
N T Ueno
,
R Ferrarotto
,
J T Chang
,
S-Y Lin
More about this publication
Annals of oncology : official journal of the European Society for Medical Oncology
Volume
32
Issue nr.
9
Pages
1194-1197
Publication date
01-09-2021
Full text links
Publisher website (DOI)
10.1016/j.annonc.2021.06.017
Europe PubMed Central
34166757
Pubmed
34166757